Genzyme Corporation drugs

17 results

  • aldurazyme

    (laronidase)
    Genzyme Corporation
    ALDURAZYME® is indicated for treating adults and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), as well as those with moderate to severe symptoms of the Scheie form. Its safety for mildly affected Scheie patients and CNS effects are not established.
    Medication Details

  • cablivi - caplacizumab

    (Caplacizumab)
    Genzyme Corporation
    CABLIVI is indicated for adults and pediatric patients aged 12 and older with acquired thrombotic thrombocytopenic purpura (aTTP), to be used in conjunction with plasma exchange and immunosuppressive therapy.
    Medication Details

  • caprelsa - vandetanib tablet, film coated

    (Vandetanib)
    Genzyme Corporation
    CAPRELSA is indicated for treating symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. It may be considered for indolent, asymptomatic, or slowly progressing cases after careful risk assessment.
    Medication Details
    Drug Interactions

  • cerdelga

    (eliglustat)
    Genzyme Corporation
    CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are categorized as extensive, intermediate, or poor CYP2D6 metabolizers, as determined by an FDA-cleared test. Limitations apply for ultra-rapid metabolizers and indeterminate genotypes.
    Medication Details
    Drug Interactions

  • cerezyme

    (IMIGLUCERASE)
    Genzyme Corporation
    Cerezyme is indicated for the treatment of adults and children aged 2 years and older with Type 1 Gaucher disease, addressing conditions such as anemia, thrombocytopenia, bone disease, and hepatomegaly or splenomegaly.
    Medication Details

  • lemtrada

    (ALEMTUZUMAB)
    Genzyme Corporation
    LEMTRADA is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including relapsing-remitting and active secondary progressive disease. It is recommended for patients who have not responded adequately to two or more MS treatments. It is not recommended for clinically isolated syndrome (CIS).
    Medication Details
    Drug Interactions

  • lumizyme

    (ALGLUCOSIDASE ALFA)
    Genzyme Corporation
    LUMIZYME® is indicated for the treatment of Pompe disease, which is characterized by acid α-glucosidase (GAA) deficiency.
    Medication Details